Lp(a) Drug Failure: Why Pelacarsen Didn’t Work and What’s Next

Key Takeaways

• Pelacarsen failed its primary endpoint: reducing cardiovascular events by 4% vs placebo — not statistically significant.
• However, it successfully lowered Lp(a) by 33%, proving the biology works — just not enough for clinical benefit.
• RNA therapies targeting Lp(a) mRNA are now the hottest frontier in preventive cardiology.
• Current Lp(a)-raising drugs (niacin, PCSK9 inhibitors) still help some patients but can’t eliminate risk for everyone.
• New agents expected in late 2027 may finally crack this stubborn genetic risk factor.

---

The Promise That Didn't Deliver

For years, cardiologists called Lp(a) (“little A”) the “forgotten risk factor.” Elevated levels run in families and dramatically increase heart attack risk — independent of cholesterol.

Drugs that lower it? There were none.

Then came pelacarsen.

Developed by Novartis and Ionis Pharmaceuticals, pelacarsen was an antisense oligonucleotide designed to silence the LPA gene in the liver, preventing production of the harmful protein.

Early results were encouraging. In Phase 2, it cut Lp(a) levels by 70%.

Researchers hoped it would translate into fewer heart attacks, strokes, and cardiovascular deaths.

But the Phase 3 trial told a different story.

What Actually Happened in Phase 3

The trial enrolled 8,000 patients with established heart disease or diabetes plus high Lp(a). They were randomly assigned to receive either pelacarsen or placebo for an average follow-up of 3.2 years.

The results:

• Lp(a) reduction: 33% average drop — biologically effective.
• Primary endpoint (cardiovascular death, heart attack, stroke): HR 0.96 (95% CI 0.87–1.06) — not statistically significant.
• No benefit in patients with the highest baseline Lp(a) (>100 mg/dL).

Translation: Lowering Lp(a) worked, but not enough to reduce real-world events.

Why It Failed

Scientists have several theories:

1. Too little, too late: Patients already had advanced disease. Maybe Lp(a) needs to be addressed decades earlier.

2. Lp(a) may be a marker, not a cause: While strongly associated with heart disease, it may not directly drive plaque formation.

3. Off-target effects: Antisense drugs can interact unpredictably with other genes.

4. Dose escalation plateau: Higher doses didn’t show proportionally greater Lp(a) reduction.

What Comes Next? The RNA Revolution

Despite the setback, interest in Lp(a)-targeted therapies remains high. Three new approaches are entering late-stage trials:

1. CRISPR-Based Gene Editing

Verve Therapeutics is developing VERVE-201, which uses CRISPR base editing to permanently switch off the LPA gene. Early results showed 87% reduction in Lp(a) after a single dose.

2. siRNA Therapy

Alnylam’s fitusiran (though originally for hemophilia) has shown secondary benefits in lowering Lp(a) by about 25%. A dedicated Phase 3 trial is launching.

3. Monoclonal Antibodies

Amarin is testing AMG-123, an experimental antibody that binds and clears Lp(a) from circulation. Preclinical data suggests near-complete elimination.

Practical Takeaways for Patients

If you have high Lp(a):

1. Get tested once — it’s genetic, so one lifetime test suffices.
2. Maximize proven therapies: Statins, aspirin, BP control, smoking cessation.
3. Consider PCSK9 inhibitors if eligible — they cut Lp(a) by ~20–30%.
4. Don’t wait for new drugs: Managing other risk factors remains the best strategy today.

Frequently Asked Questions

Q: Should I ask my doctor to test my Lp(a)?

Yes — especially if you have a strong family history of early heart disease. One test tells you everything you need to know.

Q: Is niacin still useful?

Niacin lowers Lp(a) by ~20%, but recent studies show no cardiovascular benefit and increased side effects.

Q: When will these new RNA drugs hit market?

Earliest approvals expected late 2027–2028.

Cholesterol guidelines 2026 update outlines current recommendations for managing multiple lipid risk factors, including Lp(a).

Source: Novartis Phase 3 trial results (Sept 2026). Pelacarsen lowered Lp(a) by 33% but did not reduce cardiovascular events (HR 0.96, 95% CI 0.87–1.06). Researchers conclude that greater Lp(a) reduction is needed for clinical benefit.